Medicare Advantage (MA) plans will see a 2.53% increase in payments in 2020; the FDA is developing a framework for regulatory oversight of artificial intelligence (AI); a federal court is allowing Wisconsin to withdraw 2 lawsuits from the state challenging the Affordable Care Act (ACA).
CMS has finalized a 2.53% increase in payments to Medicare Advantage (MA) plans for 2020, which they said is a reflection of a new estimate on cost growth. This is up from the 1.59% increase proposed by the agency in February, reported Reuters. The increase comes after a final estimate determined a growth rate of 5.62%, up from the 4.59% estimated in February. In 2020, MA plans will also be able to offer benefits that address beneficiaries’ social needs, such as structural changes to the home like adding ramps and widening doorways.
The FDA has released a proposed framework for tailored regulatory oversight of artificial intelligence (AI) in healthcare. According to the white paper, the agency is aiming for a framework that is based on the International Medical Device Regulators Forum risk categorization principles, FDA’s benefit—risk framework, risk management principles in the software modification guidance, and an organization-based total product lifecycle approach. The goal, according to the FDA, is to embrace AI and machine learning while also ensuring patient safety.A federal court is allowing Wisconsin’s Democratic Attorney General Josh Kaul to withdraw 2 lawsuits from the state challenging the Affordable Care Act (ACA). The first is a multistate lawsuit that resulted in a federal judge striking down the ACA, and the second is a separate multistate challenge. According to the Wisconsin State Journal, Kaul had submitted requests to remove the state from the lawsuits earlier this month following authority from a state judge.
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen